comparemela.com

Latest Breaking News On - Division of arthritis - Page 1 : comparemela.com

Atul Deodhar, MD: Long-Term Data on Bimekizumab for Ankylosing Spondylitis

During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.

United statesDivision of arthritisRheumatic diseases at oregon healthScience universityAmerican college of rheumatologyAmerican collegeAtul deodharRheumatic diseasesOregon health

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

/PRNewswire/ UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its.

Bruxelles capitaleSan diegoUnited statesUnited kingdomAntje witteMusculoskelet disordEmmanuel caeymaexAmerican college of rheumatologyImmunology solutionsDivision of arthritisOregon health science universityUs communicationsAmerican collegeExecutive vice presidentProfessor atul deodharOregon health

Ixekizumab Improves Back Pain, Morning Stiffness in Patients with PsA

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

United statesOregon health science universityDivision of arthritisOregon health science university atul deodharGroup for researchTherapeutic advancesOregon healthScience universityAtul deodharRheumatic diseasesPsoriatic arthritisAnkylosing spondylitis disease activity score

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis re.

United statesBruxelles capitaleEmmanuel caeymaexAntje witteImmunology solutionsBrand communicationsDrug administrationCorporate communications nicole hergaDivision of arthritisBrand communications eimear obrienAssessment of spondyloarthritis international societyEuropean unionOregon health science universitySpondyloarthritis international societyAnkylosing spondylitis disease activity scoreMajor improvement

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study.

United statesUnited kingdomBruxelles capitaleNicole hergaEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsBrand communicationsDrug administrationDivision of arthritisAssessment of spondyloarthritis international societyEuropean unionCorporate communications

vimarsana © 2020. All Rights Reserved.